Persistent LCMV Infection Is Controlled by Blockade of Type I Interferon Signaling
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
During persistent viral infections, chronic immune activation, negative immune regulator expression, an elevated interferon signature, and lymphoid tissue destruction correlate with disease progression. We demonstrated that blockade of type I interferon (IFN-I) signaling using an IFN-I receptor neutralizing antibody reduced immune system activation, decreased expression of negative immune regulatory molecules, and restored lymphoid architecture in mice persistently infected with lymphocytic choriomeningitis virus. IFN-I blockade before and after establishment of persistent virus infection resulted in enhanced virus clearance and was CD4 T cell-dependent. Hence, we demonstrate a direct causal link between IFN-I signaling, immune activation, negative immune regulator expression, lymphoid tissue disorganization, and virus persistence. Our results suggest that therapies targeting IFN-I may help control persistent virus infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, during viral infections, chronic type I and II IFN signaling can lead to immune suppression and a failure to clear viral infection.51-53”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [51]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Mechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491
Virus interference. I. the interferon
Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451
A diverse range of gene products are effectors of the type I interferon antiviral response
Schoggins, J. W., Wilson, S. J., Panis, M., Murphy, M. Y., Jones, C. T., Bieniasz, P., & Rice, C. M. (2011) · Nature · doi:10.1038/nature09907 · Cited by 2,433
Viral Immune Evasion Due to Persistence of Activated T Cells Without Effector Function
Zajac, A. J., Blattman, J. N., Murali-Krishna, K., Sourdive, D. J. D., Suresh, M., Altman, J. D., & Ahmed, R. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2205 · Cited by 1,978
Interferon-stimulated genes and their antiviral effector functions
Schoggins, J. W., & Rice, C. M. (2011) · Current Opinion in Virology · doi:10.1016/j.coviro.2011.10.008 · Cited by 1,289
Type I Interferons in Host Defense
Stetson, D. B., & Medzhitov, R. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.007 · Cited by 1,195
Genomic analysis of the host response to hepatitis C virus infection
Su, A. I., Pezacki, J. P., Wodicka, L., Brideau, A. D., Supekova, L., Thimme, R., Wieland, S., Bukh, J., Purcell, R. H., Schultz, P. G., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202608199 · Cited by 1,161
Interleukin-10 determines viral clearance or persistence in vivo
Brooks, D. G., Trifilo, M. J., Edelmann, K. H., Teyton, L., McGavern, D. B., & Oldstone, M. B. A. (2006) · Nature Medicine · doi:10.1038/nm1492 · Cited by 923
Self-citationIMMUNOBIOLOGY AND PATHOGENESIS OF VIRAL HEPATITIS
Guidotti, L. G., & Chisari, F. V. (2006) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100230 · Cited by 811
Cited by
Items 501–600 of 759
Autoreactive CD8 T cells in NOD mice exhibit phenotypic heterogeneity but restricted TCR gene usage
Kasmani, M. Y., Ciecko, A. E., Brown, A. K., Петрова, Г. В., Gorski, J., Chen, Y., & Cui, W. (2022) · Life Science Alliance · doi:10.26508/lsa.202201503 · Cited by 15
“In models of chronic viral infection, blocking type I IFN signaling promotes viral control, likely due to reduced CD8 T cell exhaustion (Teijaro et al, 2013; Wilson et al, 2013; Wu et al, 2016); similar mechanisms may therefore regulate the development of exhausted CD8 T cells in T1D.”
BackgroundQin, Q., Shwetank, Frost, E. L., Maru, S. Y., & Lukacher, A. E. (2016) · Journal of Virology · doi:10.1128/jvi.00199-16 · Cited by 15
“IFN-I receptor blockade has been reported to reverse CD8 T cell exhaustion and to control chronic LCMV infection (67, 75).”
BackgroundMbanwi, A. N., Wang, C., Geddes, K., Philpott, D. J., & Watts, T. H. (2016) · European Journal of Immunology · doi:10.1002/eji.201646666 · Cited by 15
Dagenais-Lussier, X., Loucif, H., Cadorel, H., Blumberger, J., Isnard, S., Bego, M. G., Cohen, É. A., Routy, J., van Grevenynghe, J., & for the Montreal Primary Infection Study Group (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1008060 · Cited by 15
T cell aging and exhaustion: Mechanisms and clinical implications
Zhang, W., Kong, D., Zhang, X., Hu, L., Nian, Y., & Shen, Z. (2025) · Clinical Immunology · doi:10.1016/j.clim.2025.110486 · Cited by 14
Verhoeven, D. E., George, M. D., Hu, W. K., Dang, A. T., Smit‐McBride, Z., Reay, E., Macal, M., Fenton, A. N., Sankaran‐Walters, S., & Dandekar, S. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302415 · Cited by 15
Interferon Control of Neurotropic Viral Infections
Milora, K. A., & Rall, G. F. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.07.005 · Cited by 13
Synthetic mimetics assigned a major role to IFNAR2 in type I interferon signaling
Zoellner, N., Coesfeld, N., Vos, F. H. D., Denter, J., Xu, H. C., Zimmer, E., Knebel, B., Al‐Hasani, H., Moßner, S., Lang, P. A., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.947169 · Cited by 13
Kim, C., Jay, D. C., & Williams, M. A. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004137 · Cited by 15
Varanasi, V., Khan, A. A., & Chervonsky, A. V. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1401750111 · Cited by 13
Govender, U., Corre, B., Bourdache, Y., Pellegrini, S., & Michel, F. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.2a0416-187rr · Cited by 14
“IFN-a/b activity has also been associated with an immunosuppressive program whose hallmarks are inhibition of proinflammatory cytokines, expression of inhibitory receptors and anti-inflammatory cytokines, and decreased T cell responses [1, 2, 5].”
BackgroundFriedrich, S.-K., Lang, P. A., Friebus‐Kardash, J., Duhan, V., Bezgovsek, J., & Lang, K. S. (2018) · Clinical & Experimental Immunology · doi:10.1111/cei.13241 · Cited by 14
Interferon regulatory factor 7 impairs cellular metabolism in aging adipose-derived stromal cells
Nodari, A., Scambi, I., Peroni, D., Calabria, E., Benati, D., Mannucci, S., Manfredi, M., Frontini, A., Visoná, S. D., Bozzato, A., et al. (2021) · Journal of Cell Science · doi:10.1242/jcs.256230 · Cited by 15
Delaloye, J., Filali-Mouhim, A., Cameron, M. J., Haddad, E. K., Harari, A., Goulet, J.-P., Gómez, C. E., Perdiguero, B., Estéban, M., Pantaleo, G., et al. (2015) · Journal of Virology · doi:10.1128/jvi.03061-14 · Cited by 14
“In a mouse model of persistent LCMV infection, type I IFNs induced chronic immune activation, and blockage of the type I IFN receptor limited immune system activation and promoted the clearance of LCMV (62, 63).”
BackgroundQuarleri, J. F., & Oubiña, J. R. (2015) · Annals of Hepatology · doi:10.5604/16652681.1184193 · Cited by 13
Jofra, T., Galvani, G., Kuka, M., Fonte, R., Mfarrej, B. G., Iannacone, M., Salek‐Ardakani, S., Battaglia, M., & Fousteri, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00811 · Cited by 13
“Type I IFNs not only promote innate and adaptive immune activation but are also responsible for the exhaustion of T cells (34, 35).”
Arenaviridae exoribonuclease presents genomic RNA edition capacityPreprint
Yekwa, E. L., Aphibanthammakit, C., Carnec, X., Coutard, B., Picard, C., Canard, B., Baize, S., & Ferrón, F. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/541698 · Cited by 13
“Despite its public health significance, and recent major contributions [21–25], Arenaviridae biology is still poorly understood.”
BackgroundCasella, V., Domenjo‐Vila, E., Esteve‐Codina, A., Pedragosa, M., Rica, P. C., Vidal, E., de la Rubia, I., López‐Rodríguez, C., Bocharov, G. A., Argilaguet, J. M., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06374-y · Cited by 13
“Taken together, our fi ndings demonstrate that the signi fi cant immune-related tissue damage observed in mice after acute LCMV infection is the cost for effective virus control.”
BackgroundLlópiz, D., Ruiz, M., Silva, L., Repáraz, D., Aparicio, B., Egea, J., Lasarte, J. J., Redín, E., Calvo, A., Angel, M., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.022 · Cited by 13
Svanberg, C., Nyström, S. N., Govender, M., Bhattacharya, P., Che, K. F., Ellegård, R., Shankar, E. M., & Larsson, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.790276 · Cited by 13
“Furthermore, the expression of PDL1 and the immune suppressive IL10, were highly dependent on type I IFN signaling in persistent viral infections (88).”
BackgroundMutant p53 leads to low‐grade IFN‐I‐induced inflammation and impairs cGAS–STING signalling in mice
Qin, Z., Liu, H., Sheng, Q., Dan, J., Wu, X., Li, H., Wang, L., Zhang, S., Yuan, C., Yuan, H., et al. (2023) · European Journal of Immunology · doi:10.1002/eji.202250211 · Cited by 12
Papatriantafyllou, M. (2013) · Nature reviews. Immunology · doi:10.1038/nri3461 · Cited by 12
Wang, F., Wang, Y. Y., Li, J., You, X., Qiu, X. H., Wang, Y. N., & GAO, F. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105636 · Cited by 12
Finetuning Type I Interferon Signaling to Enhance T Cell Immunity in HIV Infection
Mu, W., Kedia, N., & Zhen, A. (2025) · Viruses · doi:10.3390/v17060774 · Cited by 11
“This approach has shown significant promise in preclinical models of chronic viral infections [23,144,145].”
Adaptive resistance in cancer immunotherapy
Yang, K. E., Yang, C., Xiong, K., Hao, J., & Ye, L. (2026) · Cellular and Molecular Immunology · doi:10.1038/s41423-026-01424-9 · Cited by 12
“Indeed, blocking type I IFNs has been shown to improve antiviral and antitumor immune responses in both chronic lymphocytic choriomeningitis virus infection and tumors [279, 302, 303].”
Role of MicroRNA Modulation in the Interferon-α/Ribavirin Suppression of HIV-1 In Vivo
Abdel‐Mohsen, M., Deng, X., Danesh, A., Liegler, T. J., Jacobs, E. S., Rauch, A., Ledergerber, B., Norris, P. J., Günthard, H. F., Wong, J. K., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109220 · Cited by 11
Merritt, E., Londoño, M., Childs, K., Whitehouse, G. P., Kodela, E., Fueyo, A. S., & Martínez‐Llordella, M. (2020) · American Journal of Transplantation · doi:10.1111/ajt.16134 · Cited by 11
Macleod, B. L., Elsaesser, H. J., Snell, L. M., Dickson, R. J., Guo, M., Hezaveh, K., Xu, W., Kothari, A., McGaha, T. L., Guidos, C. J., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191473 · Cited by 12
“3 C), indicating that the ongoing IFN-I signaling was critical to constraining chronic virus replication and differentially affected virus control in the GIT compared with other peripheral organs (Teijaro et al., 2013; Wilson et al., 2013; Zhen et al., 2017).”
BackgroundKim, K.-S., Kim, D., Na, S., Jung, Y. S., Cho, S. J., Kim, J., Lee, I., Kim, Y.-H., Lee, C., Jeong, W., et al. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.2hi1219-762r · Cited by 12
The Yin–Yang arms of vaccines: disease-fighting power versus tissue-destructive inflammation
Tang, D.-C. C., & Nguyen, H. H. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2014.882775 · Cited by 11
“Among the many known pro- and anti-inflammatory cytokines, type I IFN plays balancing dual roles by controlling inflammation through diametrically opposed mechanisms [59,60].”
BackgroundDifferent antiviral effects of IFNα and IFNβ in an HBV mouse model
Zhou, Y., Li, S., Tang, Z., Xu, C., Huang, S., Wu, J., Dittmer, U., Dickow, J., Sutter, K., Lu, M., et al. (2016) · Immunobiology · doi:10.1016/j.imbio.2016.11.003 · Cited by 12
Transcriptional insights into the CD8+ T cell response in mono-HIV and HCV infection
Li, S.-Y., Zhang, Z., Jiang, Y., Fu, Y., & Shang, H. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02252-9 · Cited by 12
The pathogenic role of IFN-α in thyroiditis mouse models
Cheng, C., Fang, W.-F., Tang, K., & Lin, J. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120172 · Cited by 10
Démoulins, T., Baron, M., Gauchat, D., Kettaf, N., Reed, S. J., Charpentier, T., Kalinke, U., Lamarre, A., Ahmed, R., Sékaly, R., et al. (2021) · Virology · doi:10.1016/j.virol.2021.12.007 · Cited by 10
Ng, D., Maître, B., Cummings, D. T., Lin, A., Ward, L. A., Rahbar, R., Mossman, K. L., Ohashi, P. S., & Gommerman, J. L. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1501053 · Cited by 10
Pan, T., Cao, G., Tang, E., Zhao, Y., Penaloza‐MacMaster, P., Fang, Y. H., & Huang, J. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1105673 · Cited by 10
“However, during the late stages of chronic viral infection, IFN-I signaling shifts toward a pathogenic role by contributing to systemic inflammation (Teijaro et al., 2013; Wilson et al., 2013; Utay and Douek, 2016; Soper et al., 2017).”
BackgroundAguilar‐Valenzuela, R., Carlsen, E. D., Liang, Y., Soong, L., & Sun, J. (2014) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12456 · Cited by 12
Wang, G., Yoon, D., Nandi, A., Patel, K., Azar, T., Kim, J., Han, N. A., Nickie, A., Park, S., Wang, K., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.12.004 · Cited by 9
HIV and innate immunity – a genomics perspective
Rausell, A., McLaren, P. J., & Telenti, A. (2013) · F1000Prime Reports · doi:10.12703/p5-29 · Cited by 9
“What’s more, persistent production of interferon during chronic infection is thought to be deleterious [5-7].”
BackgroundMartini, H., Citro, A., Martire, C., d’Ettorre, G., Labbadia, G., Accapezzato, D., Piconese, S., Marzio, P. D., Cavallari, E. N., Calvo, L., et al. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv460 · Cited by 9
“signaling [7, 8] in chronic HCV infection, we correlated the frequency of apoptotic epitope– or HCV-specific CD8 T cells with the expression of the following ISG transcripts in T cells from patients with chronic HCV infection and healthy donors: protein kinase R (PKR) – an IFN-inducible double-stranded”
BackgroundResultInfluentialClinical Trial Design for Immune-Based Therapy of Hepatitis B Virus
Gill, U. S., & Bertoletti, A. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1600522 · Cited by 9
“Toll-free” pathways for production of type I interferons
Wang, L., & Ning, S. (2017) · AIMS Allergy and Immunology · doi:10.3934/allergy.2017.3.143 · Cited by 9
“activity; however, at late stages, a low level of prolonged IFN-I response facilitates the establishment and maintenance of persistent infection [6-11].”
BackgroundAdamska, J. Z., Verma, R., Gupta, S., Hagan, T., Wimmers, F., Floyd, K. A., Li, Q., Valore, E. V., Wang, Y., Trisal, M., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112038 · Cited by 11
Preston, S., Allison, C. C., Schaefer, J., Clow, W., Bader, S. M., Collard, S., Forsyth, W. O., Clark, M. P., Garnham, A. L., Suen, C. S. N. L. W., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05635-0 · Cited by 9
“Early blockade of IFN-I signalling does not alter the immediate number of LCMV-specific CD8 T cells but does augment enhanced control during the later stages of chronic infection [32, 33].”
BackgroundAgbayani, G., Wachholz, K., Murphy, S. P., Sad, S., & Krishnan, L. (2018) · American Journal of Reproductive Immunology · doi:10.1111/aji.13068 · Cited by 9
Type I interferons: One stone to concurrently kill two birds, viral infections and cancers
Kumar, A., Khani, A. T., & Swaminathan, S. (2021) · Current Research in Virological Science · doi:10.1016/j.crviro.2021.100014 · Cited by 9
Raja, R., Baral, S., & Dixit, N. M. (2018) · Immunological Reviews · doi:10.1111/imr.12689 · Cited by 9
Gadina, M., & O’Shea, J. J. (2024) · Science · doi:10.1126/science.adq1717 · Cited by 9
Splicing factor SRSF1 is essential for CD8 T cell function and host antigen-specific viral immunity
Juárez, I., Su, S., Herbert, Z. T., Teijaro, J. R., & Moulton, V. R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.906355 · Cited by 9
“To evaluate the role of SRSF1 in the cell-mediated immune response in viral infection, we infected WT and Srsf1-cKO mice with the lymphocytic choriomeningitis virus (LCMV)Armstrong strain in an acute infection model (Figure 2A) using established protocols (9).”
MethodSelf-citationXu, H. C., Pandey, P., Ward, H., Gorzkiewicz, M., Abromavičiūtė, D., Tinz, C., Müller, L., Meyer, C., Pandyra, A. A., Yavas, A., et al. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300637 · Cited by 8
Picat, M.-Q., Pellegrin, I., Bitard, J., Wittkop, L., Proust‐Lima, C., Liquet, B., Moreau, J., Bonnet, F., Blanco, P., Thiébaut, R., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169164 · Cited by 8
Das, R., Mishra, P., Mishra, B., & Jha, R. (2024) · Animal Feed Science and Technology · doi:10.1016/j.anifeedsci.2024.115998 · Cited by 8
Virus-associated activation of innate immunity induces rapid disruption of Peyer’s patches in mice
Heidegger, S. M., Anz, D., Stephan, N., Bohn, B., Herbst, T., Fendler, W. P., Suhartha, N., Sandholzer, N., Kobold, S., Hotz, C., et al. (2013) · Blood · doi:10.1182/blood-2013-01-479311 · Cited by 8
“During chronic virus infections, prolonged type I IFN release has been associatedwith hyperimmune activation, disruption of lymphoid tissue architecture, and disease progression.(41,42) It is thus possible that during chronic immune activation, prolonged changes in B-cell homing patterns may in fact hinder the control…”
BackgroundTeijaro, J. R. (2016) · European Journal of Immunology · doi:10.1002/eji.201546224 · Cited by 8
Self-citationRuotsalainen, J. J., Lopez-Ramos, D., Rogava, M., Shridhar, N., Glodde, N., Gaffal, E., Hölzel, M., Bald, T., & Tüting, T. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1276 · Cited by 8
IFN-β, but not IFN-α, is Responsible for the Pro-Bacterial Effect of Type I Interferon
Shaabani, N., Vartabedian, V. F., Nguyen, N., Honke, N., Huang, Z., & Teijaro, J. R. (2021) · Cellular Physiology and Biochemistry · doi:10.33594/000000370 · Cited by 10
Self-citationActin Cytoskeleton Dynamics and Type I IFN-Mediated Immune Response: A Dangerous Liaison in Cancer?
Trono, P., Tocci, A., Musella, M., Sistigu, A., & Nisticò, P. (2021) · Biology · doi:10.3390/biology10090913 · Cited by 8
“The authors demonstrated that that IFN-I signaling contributes to tissue disorganization, as shown by IFN-I blockade which preserved the splenic architecture [89].”
BackgroundInduction of appropriate T h‐cell phenotypes: cellular decision‐making in heterogeneous environments
van den Ham, H., Andeweg, A. C., & de Boer, R. J. (2013) · Parasite Immunology · doi:10.1111/pim.12053 · Cited by 9
Parallels Between the Antiviral State and the Irradiated State
McGee, H. M., Marciscano, A. E. E., Campbell, A. M., Monjazeb, A. M., Kaech, S. M., & Teijaro, J. R. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa190 · Cited by 13
“immune-regulatory molecules like PD-L1 and IL-10, promoting T-cell exhaustion and viral persistence (43,44).”
BackgroundSelf-citationZou, S., Du, Y., Huang, S., Chen, M., Yang, X., Li, S., Chen, Y., Han, M., Li, J., Yu, Q., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00034-21 · Cited by 8
“IFN-I expression leads to hyperactivation of immunity and disease progression (11, 12).”
BackgroundInterfering with type I Interferon: A novel approach to purge persistent viral infection
Wilson, E. B., & Brooks, D. G. (2013) · Cell Cycle · doi:10.4161/cc.26175 · Cited by 8
Beyond suppression: the paradox of JAK inhibitors as amplifiers of cancer immunotherapy
Žák, J., & Teijaro, J. R. (2026) · Nature reviews. Immunology · doi:10.1038/s41577-026-01266-6 · Cited by 8
“Blockade of type I interferon signalling during early lymphocytic choriomeningitis virus (LCMV) infection leads to enhanced CD4 + T cell responses and accelerated viral clearance 3,4 .”
InfluentialSelf-citationT Cell Exhaustion in Allergic Diseases and Allergen Immunotherapy: A Novel Biomarker?
Xu, Q., Li, L., & Zhu, R. (2025) · Current Allergy and Asthma Reports · doi:10.1007/s11882-025-01199-5 · Cited by 7
“Studies demonstrated that blocking IFN-I signaling reduced inhibitory molecule expression, and reversed or prevented T cell exhaustion [52, 53].”
Interleukin-4 modulates type I interferon to augment antitumor immunity
Newnes, H. V., Armitage, J. D., Buzzai, A. C., de Jong, E., Audsley, K. M., Barnes, S. A., Srinivasan, S., Serralha, M., Fear, V. S., Guo, B. B., et al. (2025) · Science Advances · doi:10.1126/sciadv.adt3618 · Cited by 7
“The dual role of IFN-I has been well reported in chronic viral settings, whereby IFN-I induces a negative feedback loop and consequent immunosuppression ( 23 – 25 ).”
Perpiñán, E., Pérez‐del‐Pulgar, S., Londoño, M., Mariñó, Z., Lens, S., Leonel, T., Bartrés, C., García‐López, M., Rodríguez‐Tajes, S., Forns, X., et al. (2020) · Journal of Viral Hepatitis · doi:10.1111/jvh.13370 · Cited by 8
Agerholm, R., Kadekar, D., Rizk, J., & Bekiaris, V. (2021) · European Journal of Immunology · doi:10.1002/eji.202149186 · Cited by 7
Loo, C. P., Snyder, C. M., & Hill, A. B. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600478 · Cited by 7
Nguyen, N. Z. N., Tran, V. G., Baek, J. Y., Kim, Y., Youn, E. H., Na, S. W., Park, S. J., Seo, S., & Kwon, B. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100495 · Cited by 7
Regulated necrosis at the crossroads of liver inflammation and cancer development
Vucur, M., Kondylis, V., Brož, P., & Luedde, T. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01147-8 · Cited by 7
Ellis-Connell, A. L., Balgeman, A. J., Harwood, O. E., Moriarty, R. V., Safrit, J. T., Weiler, A. M., Friedrich, T. C., & O’Connor, S. L. (2022) · Journal of Virology · doi:10.1128/jvi.01185-22 · Cited by 7
“There have been success in LCMV-infected mice showing that blocking IFN-I signaling could result in faster viral clearance and reduced viral loads (55).”
BackgroundChung, Y. R., Awakoaiye, B., Dangi, T., Irani, N., Fourati, S., & Penaloza‐MacMaster, P. (2024) · Journal of Clinical Investigation · doi:10.1172/jci178945 · Cited by 6
“This MAR1-5A3 antibody binds to IFN-α / β receptor subunit 1 (clone IFNAR1) and blocks binding to IFN-α and IFN-β , abrogating the induction of ISGs in vivo (19, 20, 22, 38, 39).”
Rodrigue‐Gervais, I. G., Rigsby, H., Jouan, L., Willems, B. E., & Lamarre, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102605 · Cited by 6
Draborg, A. H., Rasmussen, N. S., Larsen, J. L., Jørgensen, C. S., Sandhu, N., Skogstrand, K., Jacobsen, S., & Houen, G. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193244 · Cited by 6
Lang, E., Pozdeev, V. I., Shinde, P. V., Xu, H. C., Sundaram, B., Zhuang, Y., Poschmann, G., Huang, J., Stühler, K., Pandyra, A. A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-30627-y · Cited by 6
Innate immunity and alpha/gammaherpesviruses: first impressions last a lifetime
Jondle, C. N., & Tarakanova, V. L. (2020) · Current Opinion in Virology · doi:10.1016/j.coviro.2020.07.002 · Cited by 6
“This observation and reports of proviral IFN function during chronic LCMV infection [21,22,77] raise an intriguing possibility that herpesviruses may usurp innate immune factors to facilitate aspects of chronic infection and regulate disease development.”
BackgroundIntegrin Alpha E (CD103) Limits Virus-Induced IFN-I Production in Conventional Dendritic Cells
Duhan, V., Khairnar, V., Kitanovski, S., Hamdan, T. A., Klein, A. D., Lang, J., Ali, M., Adomati, T., Bhat, H., Friedrich, S.-K., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.607889 · Cited by 6
“, interleukin-10 (IL-10) and programmed cell death ligand 1 (PD-L1) expression (7, 8).”
BackgroundHarker, J. A., Greene, T. T., Barnett, B. E., Bao, P., Dolgoter, A., & Zúñiga, E. I. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1221562 · Cited by 6
“Type I interferon (IFN-I) signaling, while normally antiviral, when sustained at later stages of infection, has been shown to also favor viral persistence by limiting T-cell responses (9, 10).”
Autoimmunity-associated allele of tyrosine phosphatase gene PTPN22 enhances anti-viral immunity
Orozco, R. C., Marquardt, K., Pratumchai, I., Shaikh, A. F., Mowen, K. A., Domissy, A., Teijaro, J. R., & Sherman, L. A. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012095 · Cited by 8
Self-citationThe type I IFN-IL-27 axis promotes mRNA vaccine-induced CD8 + T cell responsesPreprint
Phan, A. T., Aunins, E., Cruz-Morales, E., Dwivedi, G., Bunkofske, M. E., Eberhard, J. N., Aldridge, D. L., Said, H., Banda, O., Tam, Y. K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.16.633383 · Cited by 10
Type I IFNs contribute to upregulation of PD-L1 during Chlamydia trachomatis infection
Reinhold-Larsson, N. V., & Starnbach, M. N. (2025) · Infection and Immunity · doi:10.1128/iai.00040-25 · Cited by 5
“However, chronic infections resulting in sustained type I IFN expression that correlate with increased immunosuppressive signaling, including PD-1/PD-L1, have been shown to negatively impact T-cell function and pathogen clearance (46–48).”
Chen, Y.-L., Yousif, A., Chen, C., Lowin, A. M., Saadey, A. A., Wang, S.-H., Jiang, S. S., Chen, Y., & Ghoneim, H. E. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0047 · Cited by 6
Plasmacytoid Dendritic Cell Lineage Adaptations During a Viral Infection
Chiale, C., Dallari, S., & Zúñiga, E. I. (2025) · Immunological Reviews · doi:10.1111/imr.70083 · Cited by 6
“While this IFN-I suppression is not absolute, since both IFN-I and interferon-stimulated genes can persistently be detected at low levels in tissues [156, 157], it nonetheless reflects a profound adaptation of the innate immune system occurring just days after viral infection.”
Podojil, J. R., Cogswell, A. C., Neef, T., Chiang, M.-Y., Beddow, S. A., Arellano, G., Kakade, S., McCarthy, D. P., Elhofy, A., Harp, C. T., et al. (2026) · Science Advances · doi:10.1126/sciadv.adv8860 · Cited by 5
Meeting the Challenge of Controlling Viral Immunopathology
Berber, E., Mulik, S., & Rouse, B. T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073935 · Cited by 5
Type I IFN Exhaustion is a Host Defence Protecting Against Secondary Bacterial Infections
Furuya, Y., & Müllbacher, A. (2013) · Scandinavian Journal of Immunology · doi:10.1111/sji.12107 · Cited by 10
“With a few exceptions of chronic viral infections [6, 7] , most studies agree that IFN-I is protective against acute viral infections.”
BackgroundType I IFN Signaling Is Dispensable during Secondary Viral Infection
Hosking, M., Flynn, C. T., & Whitton, J. L. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005861 · Cited by 5
“Relative to primary LCMV infection [28], peak levels of IFNα during secondary LCMV infection are substantially reduced but remain sufficient to drive the significant upregulation of a number of T1IFN dependent ISGs in the spleen at 12 hours p.”
Excessive interferon-α signaling in autoimmunity alters glycosphingolipid processing in B cells
Tan, A. H., Sanny, A., Ng, S., Ho, Y. S., Basri, N. B., Lee, A., & Lam, K. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.11.004 · Cited by 5
Self-citationImmunotherapy With Interferon α11, But Not Interferon Beta, Controls Persistent Retroviral Infection
Schwerdtfeger, M., Dickow, J., Schmitz, Y., Francois, S., Karakoese, Z., Malyshkina, A., Knuschke, T., Dittmer, U., & Sutter, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.809774 · Cited by 5
“Previous reports on chronic lymphocytic choriomeningitis virus (LCMV) infection of mice confirmed an antiviral role of type I IFNs during acute infection, but a rather detrimental role during chronic LCMV infection (22, 23).”
BackgroundWare, B. C., Sullivan, B. M., LaVergne, S. M., Marro, B. S., Egashira, T., Campbell, K. P., Elder, J. H., & Oldstone, M. B. A. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1907070116 · Cited by 5
Self-citationQiu, J., Ye, D., Chen, X. E., Dangle, N. J., Yoshor, B., Zhang, T., Shao, Y., Nallamala, V. C., Wang, S., Ren, D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.13.607862 · Cited by 5
An activating Stat1 mutant disrupts normal STAT4 innate lymphocyte programs during viral infection
Philips, R. L., Liao, Y.-C., Lau, C. M., Morrison, T. A., Jiang, K., Hutchinson, A., Shayne, J., Yao, C., Sun, J. C.-Y., Hickman, H. D., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.ado5986 · Cited by 6
Cheng, L., Li, G., Luo, F., Bi, W., Lu, M., Liu, N., Zhao, Q., Han, R. J., Wang, H., Yang, H., et al. (2026) · Cellular and Molecular Immunology · doi:10.1038/s41423-026-01398-8 · Cited by 5
The transcription factor IRF8 drives tumor-specific exhaustion in CD8+ T cells
Ongaro, M., Thouenon, R., Crespo, I., Dumez, A., Charmoy, M., Camacho, E. R., Morel, V. J., Cropp, D., Desponds, E., Zanette, G., et al. (2026) · The Journal of Experimental Medicine · doi:10.1084/jem.20252115 · Cited by 4
“We propose here a role for type I IFN, hallmark of chronic infections (Teijaro et al., 2013; Wilson et al., 2013), as repressor of IRF8 expression during chronic infection.”
Type I interferon induced during chronic viral infection favors B‐cell development in the thymus
Valbon, S. F., Lebel, M., Feldman, H. A., Condotta, S. A., Dong, M., Giordano, D., Waggoner, S. N., Melichar, H. J., & Richer, M. J. (2024) · Immunology and Cell Biology · doi:10.1111/imcb.12808 · Cited by 4
Low, Z. X. B., Yong, S. J., AlRasheed, H. A., Al‐Subaie, M. F., Kaabi, N. A., Alfaresi, M. S., Albayat, H., Alotaibi, J., bshabshe, A. A. A. A., Alwashmi, A. S. S., et al. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111279 · Cited by 4
A myeloid IFN gamma response gene signature correlates with cancer prognosis
Zhang, Y., Khanniche, A., Li, Y., Wu, Z., Wang, H., Zhang, H., Li, X., Hu, L., & Kong, X. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70139 · Cited by 4
Friebus‐Kardash, J., Christ, T. C., Dietlein, N., Elwy, A., Abdelrahman, H., Holnsteiner, L., Hu, Z., Rodewald, H.-R., & Lang, K. S. (2023) · Vaccines · doi:10.3390/vaccines11101563 · Cited by 4
“Otherwise, inhibition of the interferon type I was reported to lead to elevated activation of CD4+ T cells that play a minor role in a regular course of acute LCMV infection [5].”
InfluentialShaabani, N., Žák, J., Johnson, J. L., Huang, Z., Nguyen, N., Lazar, D. C., Vartabedian, V. F., Honke, N., Jardine, J. G., Woehl, J. L., et al. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2400042 · Cited by 5
Self-citationThree modes of viral adaption by the heart
Griffiths, C. D., Shah, M., Shao, W., Borgman, C. A., & Janes, K. A. (2024) · Science Advances · doi:10.1126/sciadv.adp6303 · Cited by 4
Nash, W., Gillespie, A., & Brown, M. G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00251 · Cited by 4
Metadata
- Authors
- Teijaro, J. R., Ng, C., Lee, A. M., Sullivan, B. M., Sheehan, K. C. F., Welch, M., Schreiber, R. D., Carlos de la Torre, J., & Oldstone, M. B. A.
- Affiliations
- Scripps Research Institute (US)
- Washington University in St. Louis (US)
- Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA.
- Corresponding author
- Teijaro, John R.
- Ng, Cherie
- Oldstone, Michael B. A.
- ORCID
- Venue
- Science
- Published
- 2013-04-12
- Volume
- 340
- Issue
- 6129
- Pages
- 207-211
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3640797
- OpenAlex
- W2024556668
- Cited by
- 755
- References
- 38
- Citations by year
- 2026: 32 · 2025: 40 · 2024: 39 · 2023: 40 · 2022: 42 · 2021: 49 · 2020: 56 · 2019: 55 · 2018: 55 · 2017: 73 · 2016: 86 · 2015: 80 · 2014: 71 · 2013: 37
- FWCI
- 50.55
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5t32ns041219-10, 5t32ai007354-30)
- National Heart, Lung, and Blood Institute (HL007195, T32HL007195)
- National Cancer Institute (R01CA043059, CA-43059, R37CA043059)
- National Institute of Allergy and Infectious Diseases (AI-077719, AI09484, AI-047140, R01AI009484, AI007354, R01AI047140, T32-AI007354., R56AI077719, R01AI077719, U54AI057160)
- National Institute of Neurological Disorders and Stroke (T32-NS041219, NS-041219)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Keywords
- lymphocytic choriomeningitis virus, viral persistence, type I interferon signaling, immune activation, negative immune regulation, CD4+ T cells, viral clearance, antiviral therapy
- MeSH terms
- Animals, Antibodies, Viral, Arenaviridae Infections, Dendritic Cells, Female, Immune Tolerance, Interferon Type I, Lymphocytes, Lymphocytic choriomeningitis virus, Male, Mice, Inbred C57BL, Spleen, Viremia, Signal Transduction, CD4-Positive T-Lymphocytes, Cytokines, Interleukin-10, Mice, Receptor, Interferon alpha-beta, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.